CASE PRESENTATION
A 55-year-old man with newly diagnosed HIV/AIDS was seen in July 2000, complaining of three months of fatigue and mild exertional dyspnea. He had been diagnosed with HIV/AIDS following a febrile illness in April 2000. At diagnosis, his CD4 count was less than 100 cells/mm 3 and his viral load was greater than 500,000 copies/mL. He had since finished treatment for both Pneumocystis carinii pneumonia (PCP) and Helicobacter cinaedi bacteremia. Despite this, he had persistent mild fatigue and dyspnea. He denied fever, chills or sweats, and otherwise felt well.
His past medical history included remote hepatitis B, hypertension, dyslipidemia and paroxysmal supraventricular tachycardia. He was an ex-smoker who had quit five months ago. He admitted to the remote use of intravenous drugs, and had both female and male sexual contacts. He had no previous rheumatological or autoimmune conditions and no history of travel or occupational exposures. He was taking trimethoprimsulfamethoxazole and azithromycin for prophylaxis of PCP and disseminated Mycobacterium avium complex infection, respectively.
His physical examination was normal; he was not hypoxic or febrile, and there was no clubbing or pulmonary findings. Pulmonary function tests showed mild obstructive lung disease. Chest radiography revealed a single, asymmetric opacity in the right upper lobe adjacent to the right hilum that was not present in April 2000, at the time of diagnosis of HIV/AIDS. Radiological interpretation suggested that it was either a composite shadow, a focal atelectasis or a focal inflammatory infiltrate. The following week, a repeat chest x-ray showed that the opacity was less prominent, and he received no treatment.
It was thought that his subjective feeling of dyspnea was related to his recent PCP infection. In July 2000, he was started on highly active antiretroviral therapy (HAART), consisting of zidovudine, lamivudine and ritonavir-boosted indinavir.
Due to the patient's ongoing mild shortness of breath and fatigue, a repeat chest x-ray was performed one month later, showing the persistence of the right upper lobe opacity. It appeared spiculated and measured approximately 1.5 cm in diameter. At this time, the patient's viral load had decreased to 2681 copies/mL and his CD4 count was 396 cells/mm 3 .
In October 2000, the patient's radiography ( Figure 1 ) and computed tomography (Figure 2 ) of the chest revealed multiple, bilateral, smooth, well-defined pulmonary nodules affecting all lobes. The larger of the nodules had a perihilar distribution and there were also multiple subpleural nodules. There were no hilar adenopathy or pleural effusions. Clinically, the patient's respiratory symptoms had improved; his viral load had dropped to 214 copies/mL and his CD4 count was 484 cells/mm 3 (Figure 3 ). Microscopic examination revealed multiple hyalinizing granulomas with keloidlike collagen in the centre (Figure 4 ). Blood vessels and small bronchi were entrapped within the hyalinizing nodules. Chronic inflammatory cells with lymphoid follicles were seen at the nodules' periphery. Special stains for acid-fast bacilli and fungi were negative. Congo red stain was negative for amyloid.
Despite the negative fungal stains, on review, the pathologist thought that the nodules could represent a fungal infection, given the patient's profound immunosuppression before starting HAART. However, an empirical three-month course of itraconazole did not improve the patient's mild respiratory symptoms or alter the radiographic appearance of the nodules. It was thought that the original diagnosis of PHG was correct. A trial of corticosteroids was considered but not initiated given the patient's minimal symptoms. Follow-up chest radiography five years later was unchanged.
DISCUSSION
PHG has no sex, race or age predilection, and usually presents with multiple bilateral pulmonary nodules (1) . Patients can be asymptomatic, or complain of mild respiratory symptoms (cough, dyspnea, hemoptysis and pleuritic chest pain) or other nonspecific symptoms (fatigue, fever and weight loss). If present, symptoms are usually nonprogressive. The nodules are slowly progressive in size and number, and there is no specific treatment. Single large nodules are sometimes amenable to surgical resection. Radiographically, the differential diagnosis includes many causes of multiple bilateral pulmonary nodules, including malignancy, granulomatous diseases such as Wegener's granulomatosis or sarcoidosis, amyloidosis, rheumatoid nodules and inflammatory pseudotumour, as well as infectious causes such as tuberculosis (TB) or histoplasmosis (1, 2, 4, 5) Pathology of the lesions in PHG shows concentric, whorled, lamellar hyaline deposits surrounded by plasma cells and lymphocytic infiltrate; early nodules show a predominance of the cellular components and older lesions show more lamellar collagenous bands (1,2). The presence of thick hyalinized collagen bands arranged in whorls, parallel arrays or in a vague storiform pattern is characteristic of PHG. Unlike Case reports (2,4,5) of PHG have described associations with prior TB, histoplasmosis and Aspergillus pulmonary infections. Others (1-5) have described associations with autoimmune conditions such as rheumatoid arthritis, multiple sclerosis, uveitis, Castleman's disease, sclerosing mediastinitis and retroperitoneal fibrosis. More than one-half of the cases in the literature have positive autoimmune serology (antinuclear antibodies, rheumatoid factor, antismooth muscle antibody, antithyroglobulin antibodies or circulating immune complexes) even in the absence of a primary autoimmune condition (2, 4) . One case in the literature described symptomatic relief with corticosteroids (5).
The etiology of PHG is unclear. PHG may represent a hyperimmune condition triggered by previous pulmonary infection or a systemic immune response secondary to collagen vascular or autoimmune disease, much as sclerosing mediastinitis and retroperitoneal fibrosis themselves can develop in response to histoplasmosis and TB (1, 5, 6) .
Our patient's multiple bilateral lung nodules were documented on computed tomography three months after beginning HAART; it is unclear whether the patient's isolated solitary right upper lobe nodule on chest x-ray one month before initiating HAART was the same process or a coincidental finding (given the nonspecific pathology of that lesion). His subjective respiratory complaints did improve even as imaging documented progression of his pulmonary nodules over the fall of 2000.
In the present case, it is possible that PHG could represent a manifestation of noninfectious immune reconstitution inflammatory syndrome (IRIS). IRIS is the pathological inflammatory response to either a previously treated or subclinical infection, temporally associated with the initiation of HAART and subsequent CD4 count recovery and virological suppression (7). IRIS was first described in 2000 by DeSimone et al (7), and typically occurs within weeks to months after the initiation of HAART. It occurs in response to previously treated or subclinical infection with TB, PCP, herpes virus, cytomegalovirus and Mycobacterium avium complex. PHG in the setting of HIV/AIDS may represent IRIS, possibly due to prior exposure to TB or fungal pathogens (which itself may be a risk factor for the development of IRIS).
A recent review (8) suggests that IRIS can occur not only with the reactivation of a latent infection, but also with either a de novo or a previously undetected autoimmune condition such as sarcoidosis, rheumatoid arthritis and Graves' disease (8) . Granulomatous diseases, such as sarcoidosis, may serve as a model with which to explain the pathogenesis of PHG in our patient. Sarcoidosis results from an exaggerated cellular immune response (possibly secondary to previous Mycobacterium infection), causing CD4+ type 1 lymphocytes to trigger ongoing and sustained T lymphocyte triggering, proliferation and activation, in turn causing the attraction and activation of macrophages that induce granuloma formation (9) . A deficiency of CD4+ cells (as seen in advanced HIV/AIDS) may inhibit granuloma formation in sarcoidosis because T lymphocytes are not present in sufficient quantities to accumulate in affected tissues. Similarly, the development of PHG in a patient beginning HAART could be a manifestation of his recovering CD4+ count and partial restoration of immune function.
CONCLUSION
PHG is a rare, benign, immune-mediated lung disease with no specific treatment. To our knowledge, this is the first described case of PHG in a patient with HIV/AIDS. Because the diagnosis of PHG was temporally preceded by the initiation of HAART, it is possible that it could have been due to an immune reconstitution phenomenon. It is well known that patients with HIV/AIDS are at risk for usual common pulmonary infections, as well as TB, PCP and other fungal pneumonias that can present as multiple pulmonary nodules. However, PHG should also be considered in the differential diagnosis of multiple pulmonary nodules in the setting of treated HIV/AIDS. 
